Affinity Asset Advisors LLC Takes $1.95 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Affinity Asset Advisors LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 150,000 shares of the company’s stock, valued at approximately $1,952,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Viridian Therapeutics by 7.8% in the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock valued at $56,632,000 after purchasing an additional 233,331 shares in the last quarter. Perceptive Advisors LLC boosted its holdings in Viridian Therapeutics by 71.1% in the fourth quarter. Perceptive Advisors LLC now owns 1,730,212 shares of the company’s stock valued at $37,684,000 after purchasing an additional 719,007 shares during the period. Vestal Point Capital LP acquired a new position in Viridian Therapeutics during the 4th quarter worth $21,780,000. Candriam S.C.A. increased its holdings in Viridian Therapeutics by 167.8% during the 2nd quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock worth $9,754,000 after purchasing an additional 469,804 shares during the period. Finally, RTW Investments LP acquired a new stake in Viridian Therapeutics in the 4th quarter valued at about $13,195,000.

Viridian Therapeutics Stock Up 0.2 %

Viridian Therapeutics stock opened at $21.17 on Wednesday. The stock has a 50 day moving average of $16.52 and a two-hundred day moving average of $15.11. Viridian Therapeutics, Inc. has a twelve month low of $10.93 and a twelve month high of $24.18. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.09 million. Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. As a group, research analysts expect that Viridian Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Insider Transactions at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 1,600,000 shares of the stock in a transaction on Friday, September 13th. The shares were bought at an average price of $18.75 per share, with a total value of $30,000,000.00. Following the acquisition, the director now owns 3,445,813 shares of the company’s stock, valued at $64,608,993.75. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.65% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on VRDN. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 target price (down previously from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Viridian Therapeutics in a report on Tuesday, September 10th. Needham & Company LLC lifted their price target on Viridian Therapeutics from $30.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. BTIG Research raised their target price on Viridian Therapeutics from $46.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Viridian Therapeutics in a report on Monday, July 29th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.30.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.